Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03372590 · ClinicalTrials.gov registry record · NA

NEO Rehab for Infants at Risk of Cerebral Palsy

A NA study of Cerebral Palsy and Prematurity, sponsored by University of Virginia.

Completed
Registry status
NA
Development phase
14
Enrollment target
1
Study location

NCT03372590: Completed NA study of Cerebral Palsy and Prematurity, sponsored by University of Virginia.

NCT03372590 is a NA study of Cerebral Palsy and Prematurity that has completed, run by University of Virginia. The registered enrollment target is 14 participants, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03372590, a NA study of Cerebral Palsy and Prematurity, has completed, sponsored by University of Virginia.

COMPLETED
Registry status
NA
Development phase
14 participants
Enrollment target
1
Study location

Study Summary

Premature infants are at increased risk of developing cerebral palsy (CP). Early interventions for at risk infants have the potential to decrease disease severity and improve quality of life. All infants demonstrate general movements (GMs), which are reliable indicators of brain function and can be reproducibly evaluated using the General Movement Assessment (GMA) tool. Prior studies have demonstrated the impact of early maternal-driven intervention strategies on neurodevelopmental outcomes in preterm infants. Investigators have shown that interventions promoting the establishment of emotional connection between the infant and his or her mother, including mother/infant calming sessions with scent cloth exchange, vocal soothing, eye contact, and kangaroo care, can impact neurodevelopmental outcomes at 18 months. Investigators have also shown that 60 minutes of kangaroo care leads to decreasing levels of the stress hormone cortisol in both mothers and infants. This pilot study aims to determine the feasibility of a maternal-driven early intervention bundle in preterm infants with abnormal GMA.

Primary Outcome

The feasibility of a maternal driven intervention bundle will be assessed using a maternal diary and unannounced observations. The ability to perform the required intervention greater than 75% of the time will be considered successful

Interventions

  • OTHER Standard of care
  • OTHER NICU-based rehabilitation bundle

Study Locations (1)

Virginia

  • University of Virginia - Charlottesville

Trial Details

FieldValue
Enrollment Target 14 participants
Start Date 2018-09-02
Est. Completion 2019-06-30
Phase NA
University of Virginia

449 total trials

What the finished NCT03372590 record still lists

NCT03372590 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 229-participant average among 91 other Cerebral Palsy trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Cerebral Palsy appearing as the primary indexed condition, and to 2 interventions - of which Standard of care is the first listed.

NCT03372590 reports a single indexed study location in Virginia.

Frequently Asked Questions

What is clinical trial NCT03372590 about?

NCT03372590 is a clinical study titled "NEO Rehab for Infants at Risk of Cerebral Palsy". Premature infants are at increased risk of developing cerebral palsy (CP). Early interventions for at risk infants have the potential to decrease disease severity and improve quality of life. All infants demonstrate general movements (GMs), which are reliable indicators of brain function and can be ...

What is the current status of trial NCT03372590?

This trial is currently completed. It is a NA study. The enrollment target is 14 participants. The study started on 2018-09-02. Estimated completion is 2019-06-30.

What conditions does trial NCT03372590 study?

This clinical trial studies the following conditions: Cerebral Palsy, Prematurity.

What interventions are being tested in trial NCT03372590?

The interventions under investigation include: Standard of care (OTHER), NICU-based rehabilitation bundle (OTHER).

Who is sponsoring clinical trial NCT03372590?

This trial is sponsored by University of Virginia, which has 449 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03372590 being conducted?

This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cerebral Palsy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03372590's enrollment target sits among peer trials

14 76th of 91 higher than 15 of 91 other Cerebral Palsy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cerebral Palsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523092 · 14 participants · Phase 4

    Use of CXCL9 as a Biomarker of Acthar Efficacy

  • NCT04263285 · 14 participants · NA

    Treatment of Depression Post-SCI

  • NCT04743271 · 14 participants · NA

    Food and Circadian Timing

  • NCT05065671 · 14 participants · Phase 1

    Microbiome Derived Metabolism and Pharmacokinetics

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT06358040 · started 2026-10 · NA

    Opioid Dispenser for Microdiscectomy/Laminectomy

Source: ClinicalTrials.gov NCT03372590, the US trial registry maintained by the National Library of Medicine. NCT03372590 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.